Dr Vicky Green
Exploiting microfluidic technology to predict chemoradiation responses in HNSCC
Project Description
Head and neck cancer (HNC) is the 6th most prevalent cancer worldwide. The mainstay of treatment involves a combination of radiation and cisplatin. Despite improvements in the delivery of these treatments, and enhanced guided radiotherapy, 3yr survival rates remain below 60%. This is largely due to locoregional recurrence and metastasis to the cervical lymph nodes, indicating resistance to the treatments leading to salvage surgery. Therefore a more selective evidence based treatment on a personalized level from the outset is required. The HNC research group in Hull have developed bespoke microfluidic devices, which are able to maintain pieces of a patients’ tumour tissue whilst being subjected to different combinations of drugs and irradiation. This approach allows the response of the tissue to be analysed, either by studying the release of soluble factors and measuring changes over time, or by analysing the tissue itself and identifying the most effective regimen on an individual patient basis. The authors believe that a sample of the patient’s own tissue is the closest representation of the whole 3D tumour available ex vivo and will mimic how the patient’s tumour will respond.
The principle aim of the project, is to correlate the response seen in the laboratory with that seen in the patient, so providing evidence that the data obtained using the microfluidic devices is directly applicable in the clinical setting. A cohort of 20 HNSCC patients, recruited over a 10 month time frame, will have samples taken at the time of diagnostic biopsy and the tumour tissue maintained on the microfluidic device will have the same treatment applied to it as is experienced by the patient, e.g. chemoradiotherapy. Alternative treatments, based on those clinically available, will be applied to additional biopsies (or resection specimens where possible) to determine whether improved options could have been available to the patient and to investigate heterogeneity. The tissue will be maintained on the device for a minimum of 4 days during which time secretions from the tissue will be monitored for markers of cell death. At the end of the experiment, the tissue will be removed from the device and analysed in terms of morphological changes, alterations in cell death and proliferation markers using immunohistochemistry and Western blotting. The patients will be followed up over 2 years by the clinical team and monitored for response to treatment; the clinical outcomes will be correlated with the responses seen in the laboratory. If, as we believe from extensive preliminary work, the correlation of clinical response with the device is high, it is envisaged that the methodology could be simply translated into the clinic, facilitating the development of translational alogarithms, based on evidence obtained on a personalised level.
Status | Project Complete |
---|---|
Value | £10,000.00 |
Project Dates | May 31, 2022 - Nov 30, 2023 |
You might also like
Blood test for clinical therapy guidance of non-small cell lung cancer patients Jan 1, 2017 - Oct 31, 2022
Lung cancer is the most common cancer worldwide. NSCLC alone make up about 75% of all lung cancers and most hospitals currently test all NSCLC patients for EGFR mutations (pharmacogenomics) for treatment decision (personalised medicine) – i.e., patie...
Read More about Blood test for clinical therapy guidance of non-small cell lung cancer patients.
The effect of corticosteroids on the release of immune modulating factors from Graves’ disease tissue maintained using microfluidic culture. Jun 1, 2017 - May 31, 2018
Graves’ disease (GD) affects approximately 2% of adult women. Current treatments for GD include anti-thyroid drugs, radioiodine therapy and surgery, of which none tackle the underlying pathogenic process. Immunosuppressive agents are therefore of gro...
Read More about The effect of corticosteroids on the release of immune modulating factors from Graves’ disease tissue maintained using microfluidic culture..
Development of a multipurpose small animal phantom for pre-clinical radiotherapy studies Apr 1, 2016 - Mar 31, 2019
The project aims to both reduce the total number of animals used for preclinical radiotherapy experiments whilst concurrently increasing the accuracy of such investigations in order to maximise their clinical impact. This will be achieved through the...
Read More about Development of a multipurpose small animal phantom for pre-clinical radiotherapy studies.
The Hull-Norwich Gut-Brian Study May 31, 2016 - Jun 30, 2018
Objective To obtain mechanistic insights into how resident commensal gut bacteria (the microbiota) influences host physiology and in particular brain function and host behaviour. The focus is on identifying the pathways and molecules originating from...
Read More about The Hull-Norwich Gut-Brian Study.
Lab on a Chip NC3Rs Engagement Award Aug 15, 2016 - Aug 14, 2017
This project will deliver a programme of public engagement with innovative hands-on activities in the area of tissue/organ-on-a-chip which are emerging as life-like models to reduce and replace animal testing to school children and the general public...
Read More about Lab on a Chip NC3Rs Engagement Award.